Anergis SA (Lausanne, Switzerland) is a clinical-stage biopharmaceutical company discovering and developing breakthrough vaccines to treat allergies caused by airborne allergens. Allergy is the fastest growing chronic condition in the industrialized world. Based on its proprietary Contiguous Overlapping Peptides (COP) technology, Anergis aims at offering patients a long-term cure from allergies and reduce the treatment time from 3-5 years to two months. Its lead program for birch pollen is in phase IIb clinical development.
Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69